Archives
-
Separating Growth Inhibition from Cancer Cell Death
2026-10-05
Hannah Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a clearer framework for distinguishing proliferative arrest from actual cell killing, while showing that drugs can affect both processes with different magnitudes and timing.
-
Epinephrine Bitartrate: From Agonism to Affinity
2026-10-05
Epinephrine Bitartrate is best understood by separating receptor activation from measured binding affinity. This evidence-focused guide examines adrenergic signaling, the analytical innovation of open-tubular capillary electrochromatography, and the limits of translating results across salts, assays, and biological systems.
-
Angiotensin 1/2 (5-7): From RAS to Viral Interfaces
2026-10-04
A source-grounded perspective on Angiotensin 1/2 (5-7), combining renin-angiotensin system biology, fragment-specific evidence, SARS-CoV-2 receptor-binding findings, translational limitations, and strategic considerations for identity-conscious peptide research.
-
From Surface Labels to Translational Models
2026-10-03
A mechanistic and strategic view of Sulfo-NHS-Biotin for translational protein studies, connecting cell-surface biology, avidin–biotin architectures, and the evidence boundaries that matter for clinical research.
-
Triptolide (PG490): Mechanism and Research Use
2026-10-02
Triptolide, also called PG490, is a nanomolar transcriptional inhibitor with immunosuppressive, pro-apoptotic, and anticancer activity. Its strongest research rationale is mechanistic: CDK7-linked RNA polymerase II disruption connects transcriptional shutdown with effects on tumor invasion, T-cell survival, and inflammatory signaling.
-
Phosphatase Inhibitor Cocktail 1: Assay Timing
2026-10-01
Phosphatase Inhibitor Cocktail 1 can protect labile phosphorylation signals during cardiac inflammation and phosphoproteomic workflows. This article shows how to align inhibitor timing, controls, and readouts with the S100A8/A9 pressure-overload study without confusing ex vivo preservation with biological causality.
-
IAA-Driven Ferroptosis in Rice Blast Conidia
2026-10-01
A 2026 Molecular Plant Pathology study identifies fungal indole-3-acetic acid (IAA) as a regulator of ferroptotic death during Magnaporthe oryzae conidial development. Genetic and supplementation experiments connect IAA with iron accumulation, lipid peroxidation, phosphatidylethanolamine metabolism, autophagy, appressorium formation, and rice blast pathogenicity.
-
TMB and the Next Era of P. vivax Serology
2026-09-30
TMB turns antibody binding into a practical optical signal, creating a bridge between immunodominant Plasmodium vivax epitope discovery and scalable translational assay development. This article examines the mechanism, validation strategy, workflow design, and strategic limits of TMB-based serology.
-
Imatinib Hydrochloride: Research Workflows
2026-09-30
Imatinib hydrochloride supports target-focused studies of v-Abl, c-Kit, and PDGFR in leukemia and solid-tumor models. This guide connects practical dose-response workflows with newer conformational insights into kinase inhibition, while separating established product data from assay-specific recommendations.
-
Cyclo (-RGDfC) for Reliable Integrin Assays
2026-09-29
Learn how Cyclo (-RGDfC), SKU A8790, can help researchers separate integrin-mediated adhesion and signaling from true viability or cytotoxicity effects. This scenario-based guide covers assay design, DMSO handling, optimization, interpretation, and vendor-quality checks.
-
DNMT3B and Neuroendocrine Prostate Cancer Plasticity
2026-09-29
The reference study identifies DNMT3B as a functional driver of therapy-associated neuroendocrine lineage plasticity and stemness in prostate cancer. Genetic and pharmacologic inhibition reduced neuroendocrine prostate cancer growth, supporting DNMT3B as an experimental target while leaving important questions about selectivity, dosing, and clinical translation unresolved.
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-09-28
Oh and colleagues developed a scalable human induced pluripotent stem cell-derived sensory neuron system that supports HSV-1 latency and experimentally induced reactivation. The model combines neuronal functional validation with virological, transcriptional, and chromatin-based criteria, providing a human-relevant platform for studying neuron-intrinsic mechanisms of persistent infection.
-
SU 5402: RTK Inhibition, Evidence, and Workflow
2026-09-28
SU 5402 is a multi-receptor tyrosine kinase inhibitor with reported activity against VEGFR2, FGFR1, and PDGFRβ, but not potent inhibition of EGFR in the reported profile. This evidence-focused guide explains its signaling effects, research uses, handling, and limits, including why results in cancer models do not establish activity in HSV-1 neuron models.
-
Protease Inhibitor Cocktail EDTA-Free: K1010 Guide
2026-09-27
K1010 is a 100X inhibitor mix used during protein extraction and sample preparation to reduce degradation by endogenous proteases. Its EDTA-free formulation suits cation-sensitive workflows such as phosphorylation analysis and enzyme assays, but it should not be treated as a metalloprotease inhibitor or as a substitute for workflow-specific compatibility testing.
-
Deracoxib and Piroxicam in Canine Osteosarcoma Cells
2026-09-26
This in vitro study compared deracoxib and piroxicam across three canine osteosarcoma cell lines and a fibroblast line, finding concentration-dependent cytotoxicity at high drug concentrations but no detectable DNA fragmentation. The results identify a cell-culture signal for further study, not evidence that either drug suppresses canine osteosarcoma at typical plasma concentrations.